Answers are grounded in this paper and cite their sources.
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a complex and heterogeneous disorder driven by dynamic interactions between genetic susceptibility, immune dysregulation, epithelial barrier dysfunction, and the intestinal microbiome. Despite significant therapeutic advances, durable remission remains elusive for many patients, reflecting an incomplete understanding of disease mechanisms within the spatially organized intestinal mucosa. Recent advances in multi-omics and spatial-omics technologies have transformed IBD research by enabling high-resolution molecular profiling while preserving tissue architecture, discovering disease-defining cellular niches and host-microbiome interactions. Simultaneously, artificial intelligence (AI) has emerged as an essential framework for integrating high-dimensional omics datasets, uncovering non-linear relationships, and translating molecular complexity into clinical applications. This review has discussed current applications of multi-omics, spatial omics, and AI-driven analyses that are reshaping disease management. Also, we discussed challenges and emerging opportunities at the intersection of omics and AI, including the development of next-generation non-animal disease models and the discovery of spatial biomarkers for disease progression and cancer risk. Therefore, integration of multi-omics, spatial omics, and AI creates a transformative approach that enhances our understanding and facilitates precision medicine in IBD.
No takes yet. Share an insight, caveat, or question.
Shirima et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: